Development of potent and selective plasmin and plasma kallikrein inhibitors and studies on the structure-activity relationship.
作者信息
Okada Y, Tsuda Y, Tada M, Wanaka K, Okamoto U, Hijikata-Okunomiya A, Okamoto S
机构信息
Faculty of Pharmaceutical Sciences, Kobe Gakuin University, Japan.
出版信息
Chem Pharm Bull (Tokyo). 2000 Dec;48(12):1964-72. doi: 10.1248/cpb.48.1964.
PMID:11145152
Abstract
Based on structure-activity relationship studies, we designed and synthesized plasmin (PL) and plasma kallikrein (PK) inhibitors. Trans-(4-aminomethylcyclohexanecarbonyl)-Tyr(O-Pic)-octylamide inhibited PL, PK, urokinase (UK) and thrombin (TH) with IC50 values of 0.53, 30, 5.3 and > 400 microm, respectively. Trans-(4-aminomethylcyclohexanecarbonyl)-Tyr(O-2-Pyrim)-4-carboxyanilide inhibited PL, PK, UK and TH with IC50 values of 36, 0.56, 440 and > 1,000 microM, respectively.
摘要
相似文献
1
Development of potent and selective plasmin and plasma kallikrein inhibitors and studies on the structure-activity relationship.
Chem Pharm Bull (Tokyo). 2000 Dec;48(12):1964-72. doi: 10.1248/cpb.48.1964.
2
Development of plasmin and plasma kallikrein selective inhibitors and their effect on M1 (melanoma) and HT29 cell lines.
Bioorg Med Chem Lett. 2000 Oct 2;10(19):2217-21. doi: 10.1016/s0960-894x(00)00431-5.
3
Structure-inhibitory activity relationship of plasmin and plasma kallikrein inhibitors.
Chem Pharm Bull (Tokyo). 2001 Nov;49(11):1457-63. doi: 10.1248/cpb.49.1457.
4
Active site-directed plasmin inhibitors: Extension on the P2 residue.活性位点定向纤溶酶抑制剂：P2残基上的延伸
Bioorg Med Chem. 2016 Feb 15;24(4):545-53. doi: 10.1016/j.bmc.2015.12.009. Epub 2015 Dec 8.
5
Development of selective inhibitors against plasma kallikrein.
Chem Pharm Bull (Tokyo). 1991 Nov;39(11):2930-6. doi: 10.1248/cpb.39.2930.
6
Development of plasma kallikrein selective inhibitors.血浆激肽释放酶选择性抑制剂的研发。
Biopolymers. 1999;51(1):41-50. doi: 10.1002/(SICI)1097-0282(1999)51:1<41::AID-BIP5>3.0.CO;2-Y.
7
Development of plasmin-selective inhibitors and studies of their structure-activity relationship.
Chem Pharm Bull (Tokyo). 2000 Feb;48(2):184-93. doi: 10.1248/cpb.48.184.
8
Amino acids and peptides. LIII. Synthesis and biological activities of some pseudo-peptide analogs of PKSI-527, a plasma kallikrein selective inhibitor: the importance of the peptide backbone.
Chem Pharm Bull (Tokyo). 1999 Aug;47(8):1141-4. doi: 10.1248/cpb.47.1141.
9
Synthesis and evaluation of tripeptidic plasmin inhibitors with nitrile as warhead.以腈为弹头的三肽类纤溶酶抑制剂的合成与评价。
J Pept Sci. 2012 Oct;18(10):620-5. doi: 10.1002/psc.2442. Epub 2012 Sep 7.
10
Development of active center-directed plasmin and plasma kallikrein inhibitors and studies on the structure-inhibitory activity relationship.
Chem Pharm Bull (Tokyo). 1993 Jun;41(6):1079-90. doi: 10.1248/cpb.41.1079.
引用本文的文献
1
X-ray crystal structure of plasmin with tranexamic acid-derived active site inhibitors.氨甲环酸衍生的活性位点抑制剂与纤溶酶的X射线晶体结构
Blood Adv. 2017 May 9;1(12):766-771. doi: 10.1182/bloodadvances.2016004150.
2
Recent advances on plasmin inhibitors for the treatment of fibrinolysis-related disorders.用于治疗纤溶相关疾病的纤溶酶抑制剂的最新进展。
Med Res Rev. 2014 Nov;34(6):1168-216. doi: 10.1002/med.21315. Epub 2014 Mar 21.
3
Extracellular alpha 6 integrin cleavage by urokinase-type plasminogen activator in human prostate cancer.尿激酶型纤溶酶原激活剂对人前列腺癌中细胞外α6整合素的切割作用
Exp Cell Res. 2004 Apr 1;294(2):550-8. doi: 10.1016/j.yexcr.2003.11.023.
Zotero 插件